Preventive and therapeutic strategies for respiratory syncytial virus infection

Respiratory syncytial virus (RSV) remains an important cause of pneumonitis in infants and in the elderly and immunosuppressed. Passive immunoprophylaxis of high-risk infants with the humanised monoclonal antibody palivizumab reduces RSV-related hospitalisation and admission to intensive care units...

Full description

Saved in:
Bibliographic Details
Published in:Current Opinion in Pharmacology 2001-10, Vol.1 (5), p.497-503
Main Authors: Vujovic, Olga, Mills, John
Format: Article
Language:English
Subjects:
Animals
Antiviral Agents - pharmacology
Antiviral Agents - therapeutic use
bronchiolitis
Humans
immunisation
Immunization, Passive
immunoprophylaxis
immunotherapy
Palivizumab
respiratory syncytial virus
Respiratory Syncytial Virus Infections - drug therapy
Respiratory Syncytial Virus Infections - immunology
Respiratory Syncytial Virus Infections - prevention & control
Respiratory Syncytial Virus Infections - virology
Respiratory Syncytial Virus Vaccines - immunology
Respiratory Syncytial Virus Vaccines - therapeutic use
Respiratory Syncytial Viruses - drug effects
Respiratory Syncytial Viruses - immunology
ribavirin
RSV-IGIV
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Respiratory syncytial virus (RSV) remains an important cause of pneumonitis in infants and in the elderly and immunosuppressed. Passive immunoprophylaxis of high-risk infants with the humanised monoclonal antibody palivizumab reduces RSV-related hospitalisation and admission to intensive care units by about 50%, although optimal and cost-effective use of this agent remains undefined. The development of an RSV vaccine is the focus of much research and recent advances with live attenuated vaccines are promising — several agents are in clinical trials. The value of the only therapeutic agent available to treat established infection, the antiviral ribavirin, is now seriously doubted and the agent is little used. New RSV chemotherapeutics are just entering clinical trials.
ISSN:1471-4892
1471-4973
DOI:10.1016/S1471-4892(01)00087-X